|
|
Volumn 7, Issue 2, 2012, Pages 141-143
|
|
Industry update: Latest developments in stem cell research and regenerative medicine
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GENE THERAPY AGENT;
LENTIVIRUS VECTOR;
LG 631;
TEMOZOLOMIDE;
UNCLASSIFIED DRUG;
BONE MARROW TOXICITY;
CANCER CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CELL SELECTION;
CLINICAL EFFECTIVENESS;
DONOR SELECTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
EMBRYONIC STEM CELL;
GLIOBLASTOMA;
HEALTH CARE INDUSTRY;
HEMATOPOIETIC STEM CELL;
HUMAN;
NON PROFIT ORGANIZATION;
PLURIPOTENT STEM CELL;
PRIORITY JOURNAL;
PUBLIC-PRIVATE PARTNERSHIP;
REGENERATIVE MEDICINE;
SHORT SURVEY;
SOCIAL MARKETING;
STEM CELL RESEARCH;
SURVIVAL TIME;
VIRAL GENE THERAPY;
|
|
EID: 84858191976
PISSN: 17460751
EISSN: 1746076X
Source Type: Journal
DOI: 10.2217/rme.12.3 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (0)
|
